

Peter A Kaufman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8941781/publications.pdf>

Version: 2024-02-01

47
papers

2,934
citations

361413

20
h-index

289244

40
g-index

48
all docs

48
docs citations

48
times ranked

3951
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P2-14-18: A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer. <i>Cancer Research</i> , 2022, 82, P2-14-18-P2-14-18.	0.9	1
2	Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 179-190.	2.5	5
3	Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. <i>Clinical Cancer Research</i> , 2021, 27, 3061-3068.	7.0	66
4	De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. <i>Oncologist</i> , 2020, 25, e214-e222.	3.7	39
5	Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. <i>Oncologist</i> , 2020, 25, e243-e251.	3.7	45
6	Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 559-565.	2.5	10
7	Effect of neuromuscular electrical stimulation on skeletal muscle size and function in patients with breast cancer receiving chemotherapy. <i>Journal of Applied Physiology</i> , 2020, 128, 1654-1665.	2.5	15
8	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. <i>Clinical Cancer Research</i> , 2020, 26, 1105-1113.	7.0	19
9	Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 665-677.	2.5	1
10	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 519-530.	10.7	441
11	A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1015-1015.	1.6	28
12	Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. <i>Clinical Cancer Research</i> , 2019, 25, 2433-2441.	7.0	62
13	SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1000-1000.	1.6	71
14	Health Through Activity: Initial Evaluation of an In-Home Intervention for Older Adults With Cancer. <i>American Journal of Occupational Therapy</i> , 2019, 73, 7305205070p1-7305205070p11.	0.3	8
15	Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. <i>Lancet Oncology</i> , The, 2018, 19, 812-824.	10.7	98
16	Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 433-440.e1.	2.4	8
17	Incongruence between women's survey- and interview-determined decision control preferences: A mixed methods study of decision-making in metastatic breast cancer. <i>Psycho-Oncology</i> , 2018, 27, 1950-1957.	2.3	6
18	Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment. <i>Journal of Biomedical Optics</i> , 2018, 24, 1.	2.6	32

#	ARTICLE	IF	CITATIONS
19	Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.. Journal of Clinical Oncology, 2018, 36, 1002-1002.	1.6	13
20	Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.. Journal of Clinical Oncology, 2018, 36, 1048-1048.	1.6	2
21	Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy.. Journal of Clinical Oncology, 2018, 36, 1049-1049.	1.6	8
22	Goal Attainment and Goal Adjustment of Older Adults During Person-Directed Cancer Rehabilitation. American Journal of Occupational Therapy, 2018, 72, 7202205110p1-7202205110p8.	0.3	14
23	Correlation of near-infrared spectral tomography (NIRST) with residual cancer burden (RCB) for prognostic assessment subsequent to neoadjuvant chemotherapy (NAC) in breast cancer.. Journal of Clinical Oncology, 2018, 36, e12655-e12655.	1.6	2
24	Evaluation of fixed-dose regimens of seribantumab in patients with solid tumors.. Journal of Clinical Oncology, 2018, 36, 2524-2524.	1.6	0
25	Collagen quantification in breast tissue using a 12-wavelength near infrared spectral tomography (NIRST) system. Biomedical Optics Express, 2017, 8, 4217.	2.9	10
26	MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology, 2017, 35, 2875-2884.	1.6	1,105
27	MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. Journal of Clinical Oncology, 2017, 35, 1000-1000.	1.6	10
28	Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2017, 35, 2555-2555.	1.6	2
29	Experience and impact of alopecia in patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry.. Journal of Clinical Oncology, 2017, 35, 239-239.	1.6	0
30	Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. Cancer Research, 2016, 76, 5933-5944.	0.9	105
31	Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer: Basic and Clinical Research, 2016, 10, BCBCR.S39615.	1.1	36
32	Dose escalation of POL6326 in combination with eribulin in HER2-negative relapsed metastatic breast cancer (mBCa) patients (pts).. Journal of Clinical Oncology, 2016, 34, 2548-2548.	1.6	0
33	Differences between women's preferred and actual experience with shared decision-making: A mixed method study.. Journal of Clinical Oncology, 2016, 34, 34-34.	1.6	5
34	Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment, 2015, 154, 509-520.	2.5	46
35	The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. Breast Cancer Research, 2015, 17, 133.	5.0	21
36	New metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research, 2015, 17, 150.	5.0	33

#	ARTICLE	IF	CITATIONS
37	Quantitative measurement of HER2 expression in breast cancers: comparison with "real-world" routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival. Breast Cancer Research, 2015, 17, 41.	5.0	29
38	Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. Journal of Clinical Oncology, 2015, 33, 594-601.	1.6	365
39	Pre-treatment Near-Infrared Spectral Tomography (NIRST) to predict pathologic complete response to neoadjuvant chemotherapy (NAC) in women with locally advanced breast cancer (LABC).. Journal of Clinical Oncology, 2015, 33, 1047-1047.	1.6	0
40	Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. Cancer, 2014, 120, 2657-2664.	4.1	47
41	The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. BMC Cancer, 2014, 14, 307.	2.6	21
42	Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 141, 461-470.	2.5	38
43	Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Research and Treatment, 2012, 135, 875-883.	2.5	51
44	Comparison of iron oxide nanoparticle and microwave hyperthermia alone or combined with cisplatin in murine breast tumors. , 2011, 7901, .		8
45	Microwave imaging for neoadjuvant chemotherapy monitoring. , 2006, , .		6
46	Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma. , 1996, 78, 1906-1911.		1
47	Bispecific monoclonal antibody therapy (anti HER-2/neu + anti CD 64) for human breast cancers that overexpress HER-2/neu. Journal of Cellular Biochemistry, 1993, 53, 255-256.	2.6	1